Abbott has reported that a trial using its CardioMEMS HF System for managing heart failure patients showed that it reduces hospitalisations.
The CardioMEMS remote monitoring sensor also showed improvement in patient-reported quality-of-life scores within three months of its use.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The MONITOR-HF trial was designed and run by the Erasmus University Medical Centre in Rotterdam. It recruited 348 patients in 25 centres in the Netherlands.
The investigator-sponsored European study demonstrated a 44% decrease in hospitalisations related to heart failure among patients with chronic heart failure who followed guideline-directed medical therapy.
The CardioMEMS sensor, a device near the size of a paperclip, is inserted into the pulmonary artery through a minimally invasive procedure. It constantly monitors pressure changes and alerts the clinical care team of the early signs of the patient’s deteriorating heart failure.
The Dutch Ministry of Health provided financial support for the controlled and randomised study while Abbott covered the clinical research organisation expenses.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAbbott heart failure business chief medical officer Dr Philip Adamson said: “Heart failure is a global health problem with a devastating impact on patient lives and high rate of morbidity and mortality.
“These results demonstrate once again that a proactive, remote-centred approach using pressure monitoring with CardioMEMS leads to better health outcomes and higher patient satisfaction across multiple health indicators than medication alone.”
The MONITOR-HF trial demonstrated that heart failure participants who were implanted with a CardioMEMS sensor experienced a significant improvement in their quality of life.
This improvement was measured using the Kansas City Cardiomyopathy Questionnaire and showed an average increase of seven points compared to the control group.
In contrast, the control group who did not receive the pressure sensor showed a decrease in their scores.
